arrow
D

Dominique C. Pichard

us food & drug administration (fda)
H指数:15
被引数:2,273

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib A Nonrandomized Clinical Trial

神经纤维瘤病1型皮肤神经纤维瘤的MEK抑制剂Selumetinib治疗:一项非随机临床试验

2025-02-260
PRE
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials
2023-10-251
PRE
The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort

腺苷脱氨酶2缺乏的谱: 对60例患者队列的观察性分析

2022-01-1051
OAAI
Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma
2020-08-150
PRE
Selumetinib in Children with Inoperable Plexiform Neurofibromas
2020-04-09391
OAAI
Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
2019-12-011
PRE